SecBot SecBot
SECBOTREPLAY Home › Report › KOD

KOD · Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share),…

Kodiak Sciences Inc. · PRESS-RELEASE filed Aug 13, 2026 at 16:00 ET

At the news

NEUTRALIMPACT 6/10

PRESS-RELEASE filed Aug 13, 2026 at 16:00 ET

Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, with R&D spending up 31% to $56.1M as clinical activities ramp. The stock's primary catalyst is the upcoming September 2026 DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in wet AMD, followed by December 2026 PEAK data for KSI-101 in MESI. Cash of $125.9M is expected to fund operations into 2027, but the widening loss and lack of revenue make this a binary event-driven pre-commercial biotech story.

  • Net loss Q2 2026: $65.6M ($1.05/share) vs $54.3M ($1.03/share) in Q2 2025
  • Cash and cash equivalents: $125.9M as of June 30, 2026
  • R&D expenses: $56.1M in Q2 2026, up from $42.8M in Q2 2025
  • DAYBREAK Phase 3 topline data (Zenkuda & KSI-501) expected September 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access